Effects of hyperprolactinemia on the tibial epiphyseal plate of mice treated with sex hormones
Carregando...
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2016
Título da Revista
ISSN da Revista
Título do Volume
Editora
TAYLOR & FRANCIS LTD
Autores
WOLFF, Roberta B.
GOMES, Regina Celia T.
AMARAL, Vinicius C. do
SIMONCINI, Tommaso
PROSDOCIMI, Fabio Cesar
SIMOES, Manuel Jesus S.
Citação
GYNECOLOGICAL ENDOCRINOLOGY, v.32, n.1, p.30-33, 2016
Resumo
The aim of this study was to evaluate the effects of metoclopramide-induced hyperprolactinemia on the tibial epiphyseal plate of hormone-treated oophorectomized mice. For this purpose, 18 animals with intact ovaries were allocated to two groups, M (metoclopramide) and V (vehicle). One hundred and eight oophorectomized animals were allocated to 12 subgroups: Oophx/V (vehicle); Ooph/M (metoclopramide); Oophx/V+E (vehicle+estradiol); Oophx/M+E (metoclopramide+estradiol); Oophx/V+P (vehicle+progesterone); Oophx/M+P (metoclopramide+progesterone); Oophx/V+T (vehicle+testosterone); Oophx/M+T (metoclopramide+testosterone); Oophx/V+E+P (Vehicle+estradiol+progesterone); Oophx/M+E+P (metoclopramide+estradiol+progesterone); Oophx/V+E+P+T (vehicle+estradiol+progesterone+testosterone); Oophx/M+E+P+T (metoclopramide+estradiol+progesterone+testosterone). After a 50-day treatment was performed histomorphometric and immunohistochemical cell death analysis. In the epiphyseal plate of the hyperprolactinemic and/or oophorectomized animals, cell proliferation and bone formation decreased, inducing intensified cell death. In the sex steroid-treated animals, estrogen boosted cell proliferation; progesterone, bone formation and testosterone, both cell proliferation and bone formation. These findings suggest that oophorectomy and hyperprolactinemia changed epiphyseal plate morphology causing cartilage degeneration. Treatment with combined sex steroids may diminish such deleterious effects.
Palavras-chave
Estrogens, hormone replacement therapy, osteoporosis
Referências
- Rossi AGZ, 2002, GYNECOL OBSTET INVES, V54, P185, DOI 10.1159/000068380
- Ben-Jonathan N, 2009, ENDOCRINOLOGY, V150, P795, DOI 10.1210/en.2008-0756
- Chahal J, 2008, PITUITARY, V11, P141, DOI 10.1007/s11102-008-0107-5
- Irie T, 2005, J BONE JOINT SURG BR, V87B, P1278, DOI 10.1302/0301-620X.87B9.15583
- Karperien M, 2005, PEDIATR NEPHROL, V20, P323, DOI 10.1007/s00467-004-1710-y
- Quereda V, 2009, J MOL ENDOCRINOL, V42, P75, DOI 10.1677/JME-08-0146
- Coss D, 2000, AM J PHYSIOL-ENDOC M, V279, pE1216
- Compston JE, 2001, PHYSIOL REV, V81, P419
- Panzan MQ, 2006, HUM REPROD, V21, P2514, DOI 10.1093/humrep/del093
- Clement-Lacroix P, 1999, ENDOCRINOLOGY, V140, P96, DOI 10.1210/en.140.1.96
- Chrysis D, 2002, ENDOCRINE, V18, P271, DOI 10.1385/ENDO:18:3:271
- Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/er.19.3.225
- Tivesten A, 2004, J BONE MINER RES, V19, P1833, DOI 10.1359/JBMR.040819
- Rickard DJ, 2002, J BONE MINER RES, V17, P580, DOI 10.1359/jbmr.2002.17.4.580
- Madden VJ, 1997, HEARING RES, V111, P76, DOI 10.1016/S0378-5955(97)00107-X
- Mackie EJ, 2008, INT J BIOCHEM CELL B, V40, P46, DOI 10.1016/j.biocel.2007.06.009
- Wolff RB, 2012, REV ASSOC MED BRAS, V58, P493, DOI 10.1590/S0104-42302012000400023
- Amaral VC, 2013, GEN COMP ENDOCR, V189, P105, DOI 10.1016/j.ygcen.2013.04.037
- Vanderschueren D, 2004, ENDOCR REV, V25, P389, DOI 10.1210/er.2003-0003
- do Amaral VC, 2015, GYNECOL ENDOCRINOL, V31, P148, DOI 10.3109/09513590.2014.967204
- Teixeira RCG, 2011, CLINICS, V66, P1101, DOI 10.1590/S1807-59322011000600031
- Ganesan K, 2008, BONE, V43, P758, DOI 10.1016/j.bone.2008.05.025
- Mandarim-De-Lacerda CA, 2003, AN ACAD BRAS CIENC, V75, P469, DOI 10.1590/S0001-37652003000400006
- Shorr E., 1941, SCIENCE, V94, P546
- Verna Carina, 2005, Rev. Bras. Ginecol. Obstet., V27, P524, DOI 10.1590/S0100-72032005000900004
- Wang Y, 1997, HISTOCHEM CELL BIOL, V108, P45, DOI 10.1007/s004180050145